Avidity Biosciences, Inc. 8-K Summary

Avidity Biosciences, Inc. – Key 8-K Summary

Event Description Avidity Biosciences, Inc. (NASDAQ: RNA) has rescheduled its special shareholder meeting from February 23, 2026, to February 26, 2026. This brief postponement allows the company to finalize preparations for the spin-off of Atrium Therapeutics, Inc. ("SpinCo"), a key step before pharmaceutical leader Novartis AG acquires Avidity. This update confirms the transaction is nearing completion and provides clarity on its imminent finalization.

Under the definitive merger agreement, Novartis AG will acquire Avidity Biosciences. As part of this transaction, Avidity will first separate its non-core assets and early-stage pipeline programs into a new, independent company, Atrium Therapeutics, Inc. Following this spin-off, Avidity shareholders will receive payment for their Avidity shares, plus a proportional distribution of shares in the new Atrium Therapeutics. This structure enables Novartis to acquire Avidity's core strategic assets—specifically its proprietary RNA-based oligonucleotide platform and lead clinical programs—while allowing the non-core assets to develop independently.

Event Timeline

• February 23, 2026: Original special shareholder meeting adjourned.
• February 26, 2026: Reconvened special shareholder meeting for Avidity investors to vote on the merger and related proposals.
• February 26, 2026: Avidity shareholders expect to receive their Atrium Therapeutics (SpinCo) shares.
• February 27, 2026: Novartis AG expects to close the merger.

Impact Assessment This transaction marks a pivotal moment for Avidity, as Novartis AG acquires the company. For current Avidity shareholders, their holdings will transform: they will exchange their Avidity shares for merger consideration and shares in Atrium Therapeutics. Novartis acquires Avidity due to its strategic interest in Avidity's innovative platform and pipeline, aiming to strengthen its therapeutic areas. Atrium Therapeutics expects to begin trading as an independent public company shortly after its distribution, likely on a major stock exchange, giving Avidity shareholders direct ownership in its future.

Financial Impact Under the definitive merger agreement, Avidity Biosciences shareholders will receive specific payment for their Avidity shares, which may include a combination of cash and/or Novartis stock. Additionally, shareholders will receive a proportional distribution of shares in the newly formed Atrium Therapeutics, Inc. The Definitive Proxy Statement, filed on January 30, 2026, details the precise value and form of this payment (e.g., cash per share, exchange ratio for Novartis stock), which this announcement does not further specify. The spin-off of Atrium Therapeutics will give Avidity shareholders direct ownership in the independent entity.

Key Takeaways for Investors This transaction offers Avidity shareholders a significant return and the chance to invest in both a global pharmaceutical leader (potentially through Novartis stock) and a new, focused biotech company (Atrium Therapeutics). Investors should understand that their Avidity holdings will convert into merger consideration and shares in Atrium Therapeutics. While this adjournment is procedural, indicating the transaction remains on track, the merger still requires customary closing conditions, such as final regulatory approvals and the successful spin-off. Any unforeseen challenges in meeting these conditions, or shifts in market sentiment, could still impact the timing or ultimate completion of the transaction. Investors should strongly review the Definitive Proxy Statement filed on January 30, 2026, for crucial details on the merger payment's value and form. They should also watch for updates on condition finalization and Atrium Therapeutics' trading start.